Clinical trials of a new water-soluble short half-life alkylating agent (S-73) administered by intra-arterial infusion into 56 patients with a variety of malignant tumors, revealed only limited usefulness. The best responses were seen in a case of Kaposi's sarcoma, a squamous cell carcinoma of the tongue, an epidermoid carcinoma of the cervix, and metastatic carcinoid to liver. In all, there were 5 good responses, 3 fair responses, 36 with no response, and 12 indeterminates. Further modifications in design and structure of S-73 are in progress to probe for greater tumor specificity.
ASJC Scopus subject areas